Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Stemcells, Inc. reports Q2 financials

Results for the quarter reflect the Company’s acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.

10 Aug 2009

Burnham as a comprehensive center in a new National Cancer Institute (NCI) Chemical Biology Consortium

The consortium will establish a new paradigm in the use of public-private partnerships to translate knowledge from leading academic institutions into new drug treatments for patients with cancer. Both the La Jolla, Calif. campus of Burnham and its new Lake Nona campus in Orlando, Fla. will participate in the consortium.

10 Aug 2009

Decode Genetics announces Q2 2009 financials

deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).

10 Aug 2009

Chemists rationally design inhibitors against an RNA molecule that causes myotonic muscular dystrophy

Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.

9 Aug 2009

Genetic profiling of tumors could have 'immediate impact' on treating cancer

New work by MIT cancer biologists shows that the interplay between two key genes that are often defective in tumors determines how cancer cells respond to chemotherapy.

6 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Innovative diabetes drug discovery partnership

The Juvenile Diabetes Research Foundation said today that it has entered into a novel collaborative research agreement with the Genomics Institute of the Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform.

5 Aug 2009

New microchip technology may accelerate drug discovery for cancer, other diseases

Flasks, beakers and hot plates may soon be a thing of the past in chemistry labs. Instead of handling a few experiments on a bench top, scientists may simply pop a microchip into a computer and instantly run thousands of chemical reactions, with results - literally shrinking the lab down to the size of a thumbnail.

From Siemens Healthineers 3 Aug 2009

Covance enters strategic genomic services agreement with Merck

Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.

30 Jul 2009

Schering Plough’s CMO ‘very concerned’ about Obama’s healthcare reform agenda

Robert Spiegel, Senior Vice President and Chief Medical Officer for Schering-Plough Corporation (NYSE: SGP), the global science-based healthcare company, says he is "very concerned" that changes to the healthcare system by the Obama administration could affect public health.

22 Jul 2009

Parabon NanoLabs awarded research grant to develop novel cancer therapeutics

Parabon NanoLabs, a leading designer and manufacturer of breakthrough products at the nanoscale, announced today its award of a National Science Foundation (NSF) Small Business Innovative Research (SBIR) grant.

21 Jul 2009

New nanoparticles could revolutionize therapeutic drug discovery

Understanding the structure of proteins is a vital first step in developing new drugs, but to date, researchers have had difficulty studying the large number of proteins that are normally embedded in the cell membrane, a family of proteins that includes those involved in cancer-related signaling processes.

21 Jul 2009

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

15 Jul 2009

Novel drug discovery tool could bring new therapies for Parkinson’s

Researchers funded by the National Institutes of Health have turned simple baker?s yeast into a virtual army of medicinal chemists capable of rapidly searching for drugs to treat Parkinson's disease.

13 Jul 2009

Delirium in hospitalized adults: Situation critical, no relief available

Every year as many as seven million adults in the United States experience delirium during hospitalization. In a systematic review of the scientific literature on delirium prevention and treatment, investigators from the Regenstrief Institute, Indiana University, and Wishard Health Services found that despite the significant health and financial burdens of delirium for hospitalized adults, no effective way to prevent or treat the condition has been identified.

6 Jul 2009

Discovery of a genetic link to risk of kidney stones and osteoporosis

A discovery by scientists at deCODE genetics and academic colleagues from Iceland, the Netherlands and Denmark has pointed to a common biological mechanism contributing to both kidney stones and decreased bone mineral density (BMD).

30 Jun 2009

New protein stabilisation technique could revolutionise therapeutic drug discovery

A revolutionary new protein stabilisation technique has been developed by scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) which could lead to 30 per cent more proteins being available as potential targets for drug development - opening up exciting possibilities in drug discovery.

25 Jun 2009

Scientists block Ebola infection in cell-culture experiments - could lead to first therapy

Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells.

23 Jun 2009

Targeting tumor behavior may find new anti-cancer agents

Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior. The agents target multiple genes associated with that behavior at one time.

18 Jun 2009

Distributed drug discovery for neglected diseases

Researchers from Indiana University-Purdue University Indianapolis (IUPUI) have developed Distributed Drug Discovery (D3), a new low-cost strategy to accelerate the discovery of drugs to treat neglected diseases such as tuberculosis, leprosy, leshmaniasis, dengue fever, and Chagas disease.

16 Jun 2009